14 July 2026
Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZeneca
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Joshua Hofheimer Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Ruchun Ji Lead | Sidley | Not stated | M&A and Private Equity | Not stated |
| Jean Qiu Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Vadim Brusser | Sidley | Not stated | Antitrust and Competition | Not stated |
| Francesca Blythe | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
| Chen Yang | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Miriam Carroll Silvestri | Sidley | Not stated | Antitrust and Competition | Not stated |
| Jason Menzies | Sidley | Not stated | Tax | Not stated |
| Taylor Ishida | Sidley | Not stated | M&A | Not stated |
6 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 200m (US$200 million)
- What the figure measures
- Not stated
- Client
- Sino Biopharmaceutical Limited
- Counterparties
- AstraZeneca